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Abstract
The central event in prion diseases is the conformational conversion of the cellular prion protein (PrP
C) into PrP
Sc, a partially
protease-resistant and infectious conformer. However, the mechanism by which PrP
Sc causes neuronal dysfunction remains
poorly understood. Levels of Shadoo (Sho), a protein that resembles the flexibly disordered N-terminal domain of PrP
C, were
found to be reduced in the brains of mice infected with the RML strain of prions [1], implying that Sho levels may reflect the
presence of PrP
Sc in the brain. To test this hypothesis, we examined levels of Sho during prion infection using a variety of
experimental systems. Sho protein levels were decreased in the brains of mice, hamsters, voles, and sheep infected with
different natural and experimental prion strains. Furthermore, Sho levels were decreased in the brains of prion-infected,
transgenic mice overexpressing Sho and in infected neuroblastoma cells. Time-course experiments revealed that Sho levels
were inversely proportional to levels of protease-resistant PrP
Sc. Membrane anchoring and the N-terminal domain of PrP
both influenced the inverse relationship between Sho and PrP
Sc. Although increased Sho levels had no discernible effect on
prion replication in mice, we conclude that Sho is the first non-PrP marker specific for prion disease. Additional studies using
this paradigm may provide insight into the cellular pathways and systems subverted by PrP
Sc during prion disease.
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Introduction
Prion diseases, such as Creutzfeldt-Jakob disease (CJD) in
humans, bovine spongiform encephalopathy (BSE), and chronic
wasting disease (CWD) in cervids, are invariably fatal neurode-
generative disorders caused by the accumulation of misprocessed
prion protein (PrP
Sc) in the brain. The central pathognomonic
event in prion diseases is the post-translational refolding of the
cellular prion protein (PrP
C) into PrP
Sc, a partially protease-
resistant and b-sheet-enriched conformation that is infectious
[2,3]. Mice lacking PrP
C fail to develop prion disease and do not
propagate infectious prions in their brains, indicating that PrP
C
expression is required for prion replication [4,5]. Despite a clear
involvement in pathogenesis, the mechanism by which PrP
Sc
causes neuronal dysfunction during prion disease remains obscure.
Although PrP
C is known to interact with or reside in close spatial
proximity to numerous other proteins in the cell membrane
[6,7,8], none of these identified proteins has been shown to be
associated with prion disease pathogenesis or prion replication.
The mammalian prion protein family consists of three
members: PrP
C; Doppel (Dpl), a testes-specific protein involved
in the proper functioning of the male reproductive system [9,10];
and Shadoo (Sho), a recently identified neuronal paralog of PrP
C
encoded by the Sprn gene [1,11]. Unlike Dpl, which resembles the
alpha-helical C-terminal domain of PrP
C [12], Sho is reminiscent
of the flexibly disordered N-terminal domain of PrP. In particular,
the similarity between PrP and Sho is striking within the alanine/
glycine-rich hydrophobic tract. This region of PrP is of particular
interest because (i) it is the most-conserved region among PrP
ortholog sequences; (ii) it is conformationally altered in PrP
Sc [13];
(iii) its deletion renders PrP toxic to cerebellar neurons [14,15];
and (iv) deletions within this region result in a loss of PrP
C-
associated neuroprotective activity [1]. Like PrP
C, Sho is an N-
glycosylated GPI-anchored protein that is expressed in the brain
and exhibits neuroprotective properties in response to various
neurotoxic stimuli in cells [1,16]. Both PrP
C and Sho undergo
endoproteolytic cleavage just N-terminal to the hydrophobic tract
to generate a C-terminal fragment termed C1 [1,17]. PrP
C is also
cleaved in the vicinity of residue 88 to generate a distinct C-
terminal fragment termed C2 [17]. Production of the C2 fragment
is greatly increased during prion disease, likely due to the inability
of the cell to clear aggregated PrP
Sc via lysosomal degradation
[18,19]. Although the biological role of Sho in the brain is
currently unknown, knockdown of Sprn in mouse embryos lacking
PrP expression results in a lethal phenotype [20], arguing for an
overlapping function with PrP
C. However, Sho levels are
unchanged in the brains of adult mice lacking PrP
C [1], indicating
that cross-regulation of protein expression does not occur between
the two proteins.
PLoS Pathogens | www.plospathogens.org 1 November 2011 | Volume 7 | Issue 11 | e1002382The influence, if any, of Sho on prion replication and
pathogenesis remains to be evaluated. Analogously to Prnp
encoding the prion protein, polymorphisms have been identified
in the human, ovine, and murine Sprn genes; whether these are
linked to prion disease incubation time or susceptibility is not
completely understood [21,22,23,24]. Recently, it has been shown
that Sho protein levels are reduced in the brains of clinically ill
mice infected with the RML strain of prions [1]. This observation
suggests that Sho protein levels may be inherently linked to prion
replication or reflect the presence of PrP
Sc in the brain. Indeed,
Sho is known to reside in spatial proximity to PrP
C within the cell
membrane as demonstrated by cross-linking experiments [8].
Furthermore, nonsense mutations in the SPRN gene were found in
two patients with variant CJD, but not in control patients [21].
These results argue that a thorough evaluation of the effect of Sho
on prion disease is warranted.
Here we report that levels of Sho and PrP
Sc were inversely
correlated in the brains of prion-infected rodents and sheep. This
association was observed for 14 different prion strains and
required the presence of the N-terminal domain of PrP.
Furthermore, Sho overexpression did not influence the kinetics
of prion replication in mice. Additional studies of the relationship
between Sho and PrP may help to reveal neurotoxic mechanisms
utilized by PrP
Sc during prion disease.
Results
Decreased Sho levels in the brains of prion-infected
rodents and sheep
Previously, it was shown that Sho protein levels were reduced in
the brains of clinically ill, wild-type (wt) mice infected with the
RML strain of prions [1]. To investigate whether this phenom-
enon occurs with other prion strains and other animal species, we
examined Sho levels in the brains of wt CD-1 mice, meadow voles,
and sheep infected with prions. Consistent with previous findings,
Sho levels were notably reduced in the brains of wt CD-1 mice and
meadow voles infected with RML prions at the onset of
neurological symptoms (Figure 1A). In addition, we observed
diminished Sho levels in the brains of three sheep with natural
(non-experimental) scrapie and in a sheep inoculated with the
CH1641 scrapie strain [25] (Figure 1B). Sho levels also were
decreased in RML-infected Tg(NSE-MoPrP) mice, which selec-
tively express PrP
C in neurons (Figure 1C).
Despite the reduction in Sho protein levels in prion-infected
mice, Sprn mRNA levels did not decrease in two different lines of
wt mice (FVB and C57BL/6) infected with RML prions relative to
mice inoculated with uninfected brain homogenate (Figure 1D;
data from [26]), consistent with findings from others [22,27].
Thus, depletion of Sho during prion disease occurs via a post-
transcriptional process.
A recent paper demonstrated that recombinant Sho readily
converts to amyloid under physiological conditions [28]. We
therefore tested if sequestration of Sho in large SDS-insoluble
aggregates within prion-infected brains hinders the detection of
Sho by Western blotting. We solubilized prion-infected hamster
brains with 6 M guanidine hydrochloride but found no increase in
the Sho signal (Figure S1), arguing that Sho does not form
insoluble aggregates in the brains of prion-infected rodents.
Inverse relationship between Sho and PrP
Sc levels during
prion disease
To investigate the relationship between Sho and PrP
Sc levels, we
examined Sho levels in wt FVB mice at different time points
following inoculation with RML prions. At 74 days postinocula-
tion (dpi), Sho levels in the brain began to decrease as protease-
resistant PrP
Sc first became visible by Western blotting
(Figure 2A). As PrP
Sc levels continued to increase until the mice
reached the clinical phase of prion disease at 133 dpi, Sho protein
levels also decreased progressively. Relative quantification of Sho
and PrP
Sc levels in the brains of RML-infected mice revealed that
the inflection points for Sho depletion and protease-resistant PrP
Sc
accumulation were at ,70 dpi (Figure 2B), although small
amounts of protease-resistant PrP
Sc were apparent by 60 dpi.
Statistical analysis revealed an inverse correlation between Sho
and protease-resistant PrP
Sc levels (Figure 2C).
Decreased Sho levels in diverse Tg models of prion
disease
We next investigated whether Sho levels decrease upon prion
infection with other strains and in other animal species. In wt FVB
mice (which express the PrP-A allotype), we examined 3 additional
prion strains: 22L, Me7, and 301V (Figure 3A). Both 22L and
Me7 prions originated from sheep with scrapie, like RML prions,
and were passaged in wt mice [29,30]. The 301V strain was
derived from passage of brain homogenate from a cow with BSE
to VM mice [31], and then passaged in B6.I mice, which express
the PrP-B allotype, or in FVB mice (Figure 3A). Another mouse-
passaged scrapie strain, 87V [32], was also passaged in B6.I mice.
In all cases, Sho levels in the brain, examined at the onset of
neurological symptoms, were depleted in response to prion
infection.
Similarly, a near-complete reduction in Sho levels was observed
in hamsters infected with the Sc237, 139H, HY, or DY strains of
prions (Figure 3B). Sc237 prions originated from sheep with
scrapie, then passaged in Syrian hamsters; 139H was also isolated
in scrapie-infected sheep, passaged first in mice then in Syrian
hamsters [33]. HY and DY were isolated by passage of
transmissible mink encephalopathy (TME) prions into Syrian
hamsters [34]. The incubation periods for all prion strain-host
combinations examined are shown in Table S1.
We also tested whether Sho levels were diminished in response
to infection with naturally occurring prion strains. SSBP/1 scrapie
prions were injected into transgenic (Tg) mice expressing ovine
PrP, and elk CWD prions were inoculated in Tg mice expressing
elk PrP (Figure 3C). In addition, Tg mice expressing human PrP
with either the M129 or V129 polymorphism were infected with
sporadic CJD prions of subtype MM1 and VV2, respectively
(Figure 3D). All inoculated Tg mice showed decreased Sho levels
Author Summary
Shadoo is a protein that resembles the prion protein,
which causes prion diseases such as Creutzfeldt-Jakob
disease in humans and ‘‘mad cow’’ disease. In this paper,
we demonstrate that during prion disease in animals,
levels of Shadoo were reduced in the brain and correlated
with levels of infectious prions. This phenomenon
occurred following infection with 14 different prion strains
but was not observed following the accumulation of other
aggregated proteins, including those that cause Alzhei-
mer’s disease and Parkinson’s disease. Thus, Shadoo levels
in the brain are a specific indicator of prion disease status,
and it may be possible to exploit this observation for
diagnostic purposes. Although we show that Shadoo itself
is unlikely to influence prion disease, using Shadoo as a
tool to probe the biology of prions may be a useful
strategy for deciphering how prions damage the brain.
Shadoo and PrP
Sc
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Sc accumulated during prion disease. Taken together, these
results demonstrate that Sho depletion in the brain occurs in
different animal species in response to a variety of prion strains.
Decreased Sho in prion-infected cultured cells
Next, we assessed whether Sho levels were decreased in cultured
cells replicating prions. Because N2a neuroblastoma cells express
very low levels of endogenous Sho that are not detectable by
Western blotting [8], we generated an N2a cell line that stably
overexpresses Sho; these cells are denoted N2a-Sho (Figure 4A).
Western blot analysis revealed that the Sho protein expressed in
N2a-Sho cells exhibited similar biochemical properties to Sho in
mouse brains [1], including N-glycosylation and endoproteolytic
processing to generate a C-terminal (ShoC1) fragment
(Figure 4A).
Similar to ScN2a cells that stably propagate RML prions [35],
N2a-Sho cells were infected with RML prions, and denoted
ScN2a-Sho cells. Following extensive passage to remove all traces
of the inoculum, Sho levels were assessed in infected ScN2a-Sho
cells. For comparison, Sho levels were also determined in
uninfected N2a-Sho cells. No consistent decrease in Sho levels
was observed in infected ScN2a-Sho cells despite the presence of
protease-resistant PrP (Figure 4B, C). Because N2a cells show
heterogeneous potential for infection with prions, even in clonal
populations of cells [36], we performed further subcloning of the
ScN2a-Sho cells in order to isolate subclones that were more
uniformly infected. Two such subclones with the highest levels of
protease-resistant PrP
Sc (referred to as ScN2a-Sho-1 and ScN2a-
Sho-2 cells) were selected for further analysis. In these lines, Sho
levels were decreased by 40–45%, a significant reduction
compared to Sho levels in uninfected N2a-Sho cells (Figure 4B,
C). These results demonstrate that Sho reduction can also occur in
cultured cells as a result of prion infection. In contrast, we did not
observe any change in Sho following amplification of hamster
Sc237 prions in vitro by protein misfolding cyclic amplification
(PMCA), a cell-free system for studying prion replication [37]
(Figure S2).
Decreased Sho is specific for protease-resistant PrP
Sc
To address the specificity of Sho depletion to prion disease, we
examined levels of Sho in the brains of mice with other
neurodegenerative illnesses not associated with the accumulation
of protease-resistant PrP
Sc. These mice include two Tg mouse
models of Alzheimer’s disease (AD); Tg(MoDpl)/Prnp
0/0 mice that
show cerebellar degeneration as a result of Dpl expression [38]; a
Tg mouse model of Parkinson’s disease; and a Tg mouse model of
Figure 1. Decreased Sho protein levels in the brain during experimental and natural prion disease. (A) Western blot analysis of Sho
protein levels in the brains of clinically ill wt CD-1 mice and meadow voles infected with RML prions. Sho levels were notably reduced in prion-
infected brains compared to the uninfected brains, as probed by two distinct anti-Sho antibodies (the N-terminal antibody 06rSH-1 and the C-
terminal antibody 06SH-3a). Prion disease is indicated by the presence of PK-resistant PrP in infected brains. (B) Decreased Sho levels in the brains of
three sheep with natural scrapie as well as a sheep inoculated with the CH1641 scrapie strain compared to brains from healthy control animals. (C)I n
Tg(NSE-MoPrP) mice, PrP
C expression is under the control of the neuron specific enolase (NSE) promoter and restricted to neurons. RML prion-
infected Tg(NSE-MoPrP) mice exhibited diminished Sho protein levels compared to uninfected mice. (D) Sprn mRNA levels in wt FVB (black) and
C57BL/6 (gray) mice (log2 change compared to mice inoculated with uninfected brain homogenate) remained relatively constant after infection with
RML prions, arguing that the depletion of Sho protein levels during prion disease is a post-transcriptional process. Sprn mRNA data was extracted
from the Prion Disease Database [26]. For Western blots, actin levels are shown as controls. PrP was probed using the antibodies HuM-D18 (A, C)o r
HuM-P (B). Molecular masses based on the migration of protein standards are shown in kilodaltons.
doi:10.1371/journal.ppat.1002382.g001
Shadoo and PrP
Sc
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and Tg(CRND8) mice [39,40], expression of mutant amyloid
precursor protein results in the progressive accumulation of Ab.
Despite high levels of cerebral Ab accumulation in aged
Tg(APP23) and Tg(CRND8) mice, Sho levels were similar to
those in wt mice and younger control mice (Figure 5A). Similarly,
Sholevelsinthe brainsofTg(MoDpl)/Prnp
0/0micedidnot diminish
as a result of Dpl-induced degeneration (Figure S3). In
Tg(SNCA,A53T) mice that express mutant human alpha-synuclein
associated with Parkinson’s disease, Sho levels were also unaltered
(Figure S4). Tg(MAPT,P301S) mice do not show decreased Sho
levels in their brains despite expressing mutant human tau causing
frontotemporaldementia(FigureS4). Together,theseobservations
argue that Sho depletion in the brain is a specific indicator of
protease-resistant PrP
Sc accumulation in prion disease.
Next, we investigated Sho levels in Tg mice with a
neurodegenerative illness characterized by the accumulation of
protease-sensitive PrP
Sc in the brain. Tg mice expressing mutant
MoPrP(P101L), analogous to the P102L mutation causing
Gerstmann-Stra ¨ussler-Scheinker (GSS) disease in humans, show
spongiform degeneration and astrocytosis reminiscent of prion
disease but do not harbor protease-resistant PrP
Sc in their brains
[41,42]. However, the disease was transmissible to Tg mice
expressing lower levels of mutant PrP(P101L), arguing for the
presence of protease-sensitive PrP
Sc [43,44]. Only a small decrease
in Sho levels was observed in the brains of clinically ill
Tg(MoPrP,P101L) animals compared to the reduction observed
in wt mice infected with RML prions (Figure 5B, C). PrP in the
brains of these animals was precipitable by PTA but sensitive to
PK digestion, arguing for the presence of protease-sensitive PrP
Sc.
Sho levels were also not substantially decreased in mice infected
with MoSP2 prions (Figure 5D), a protease-sensitive synthetic
prion strain generated from recombinant PrP amyloid [45]. The
presence of protease-sensitive PrP
Sc in the brains of MoSP2-
infected mice was confirmed by their ability to seed the
polymerization of recombinant PrP in the real-time quaking-
induced conversion (RT-QuIC) assay [46], which is derived from
the amyloid seeding assay [47]. Cumulatively, these results argue
that Sho is a specific indicator of protease-resistant PrP
Sc
conformations in the brains of animals with prion disease.
Interaction between Sho and PrP in prion-infected cells
To investigate whether Sho and PrP
Sc directly interact with
each other, we performed coimmunoprecipitation analyses. When
Sho was immunoprecipitated from ScN2a-Sho-1 cells, coprecipi-
tation of PrP was observed (Figure 6). In contrast, no
copurification of PrP was observed when the immunoprecipitation
was performed on uninfected N2a-Sho cells, suggesting that Sho
binds to misfolded PrP but does not interact with PrP
C.A sa
control for the non-specific binding of aggregated forms of PrP
Sc to
the immunoprecipitation matrix, we performed immunoprecipi-
tations on ScN2a-Sho cells in which the anti-Sho antibody was
omitted. No copurification of PrP was observed under these
conditions. Furthermore, only minute amounts of PrP were
observed after performing Sho immunoprecipitations on ScN2a
cells, which do not express detectable levels of Sho (Figure 6).
These results indicate that Sho possesses an intrinsic ability to bind
misfolded PrP, providing a potential mechanism for the PrP
Sc-
correlated depletion of Sho during prion disease.
Sho overexpression does not influence incubation times
Having shown that Sho levels are linked to protease-resistant
PrP
Sc levels in the brains of prion-infected mice, we next asked
whether Sho levels have any effect on prion replication. We
therefore generated Tg mice overexpressing murine or human Sho
under the control of the hamster Prnp promoter, denoted
Tg(MoSho) and Tg(HuSho) mice, respectively. Two independent
Tg(MoSho) lines were obtained, which express Sho in the brain at
approximately 12- and 20-fold the levels present in the brains of wt
Figure 2. Inverse relationship between Sho and PrP
Sc levels
during prion disease in mice. (A) Western blotting of Sho and
protease-resistant PrP
Sc in brain homogenates prepared from wt mice
infected with RML prions at the indicated days postinoculation (dpi). As
Sho signals began to decrease, protease-resistant PrP
Sc increased. Actin
levels are shown as a control. Molecular masses based on the migration
of protein standards are shown in kilodaltons. Sho and PrP were probed
using the antibodies 06rSH-1 and HuM-P, respectively. (B) Quantifica-
tion of relative Sho (black) and PK-resistant PrP
Sc (gray) levels in RML-
infected mice at the indicated days postinoculation. The inflection
points for Sho reduction and PrP
Sc accumulation both occurred at ,70
dpi. (C) Correlation analysis of Sho and PK-resistant PrP
Sc levels in the
brains of RML-infected mice (n=29). A significant, inverse correlation
(P,0.0001; R
2=0.85) was observed, indicating that increased protease-
resistant PrP
Sc levels are associated with decreased Sho levels in the
brain.
doi:10.1371/journal.ppat.1002382.g002
Shadoo and PrP
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generated. Both Tg(MoSho) lines remained free of neurological
symptoms up to 500 days of age. At older ages, a proportion of
Tg(MoSho) mice began to exhibit signs of neurological illness
including circling, ataxia, and dysmetria (Figure S5). No
Thioflavin S–reactive deposits were observed in the brains of
aged Tg(MoSho) mice, indicating that overexpression of Sho did
not lead to the formation of amyloid in the brain. The most
prominent neuropathological finding in aged Tg(MoSho) mice was
mild vacuolation accompanied by astrocytic gliosis, predominantly
in white matter tracts (Figure S5). However, these changes are
consistent with normal aging in mice, indicating that prolonged
overexpression of Sho likely has minimal consequences for normal
brain homeostasis.
As determined by Western blotting, Sho protein in the brains
from both lines of Tg(MoSho) mice exhibited N-glycosylation and
was subject to endoproteolytic trimming to generate the ShoC1
fragment (Figure 7A). Levels of PrP
C were unchanged in
uninfected Tg(MoSho) and Tg(HuSho) mice compared to wt
mice (Figure 7B), confirming the absence of cross-regulation of
protein expression between the two proteins. Tg(MoSho) mice
were then inoculated with three different mouse-adapted prion
strains: RML, Me7, and 301V. Incubation periods for the three
inocula were not substantially different between wt mice and
Tg(MoSho) mice (Table 1). For RML prions, no significant
difference (P.0.05 by the Log-rank test) was observed between the
survival curves for wt mice and either of the Tg(MoSho) lines
(Figure 7C), indicating that Sho levels do not influence the
incubation period in mice. Infection of either line of Tg(HuSho)
mice with RML prions also failed to alter the incubation period
compared to that of wt mice (Table 1). The banding pattern and
level of PK-resistant PrP
Sc in the brains of RML-infected,
Tg(MoSho) mice was similar to that of RML-infected, wt mice
(Figure 7D). Neuropathological signs of prion disease, including
spongiform degeneration and PrP deposition, were similar in
prion-infected Tg(MoSho) mice and infected wt FVB mice,
regardless of the prion strain used (Figure 7E–J, S6). In contrast
to a recent report [48], we found no evidence of Thioflavin S–
reactive amyloid deposits in the brains of prion-infected
Tg(MoSho) or Tg(HuSho) mice. Collectively, these results argue
that increased Sho levels in the brain do not modulate prion
disease in mice.
We next examined Sho levels in the brains of prion-infected
Tg(MoSho) mice. By Western blotting, Sho levels were clearly
decreased in the brains of RML-inoculated Tg(MoSho) mice
sacrificed at the onset of clinical signs of prion disease, compared
to age-matched, uninfected controls (Figure 8A). Levels of full-
length Sho and the ShoC1 fragment decreased proportionately in
prion-infected Tg(MoSho) mice (Figure 8B). Quantification of
Sho levels in wt and Tg(MoSho) mice at the onset of clinical prion
disease revealed that Sho levels decreased ,70% in each line,
regardless of the initial Sho expression level (Figure 8C). This
observation may indicate that there are two distinct pools of Sho in
the brain: one that can be eliminated by the presence of protease-
resistant PrP
Sc and one that is refractory to this phenomenon.
Furthermore, it suggests that Sho levels are substoichiometric to
Figure 3. Decreased Sho levels in different animal models infected with diverse prion strains. (A) Western blot analysis of brain
homogenates prepared from wt FVB mice (expressing the PrP-A allotype) infected with RML, 22L, Me7, and 301V prions, and B6.I mice (expressing the
PrP-B allotype) infected with 87V and 301V prions. All inoculated mice developed prion disease, as indicated by the presence of protease-resistant
PrP
Sc, and showed decreased Sho levels. (B) Western blot analysis of brain homogenates from hamsters infected with Sc237, 139H, HY and DY prion
strains. All inoculated hamsters developed prion disease, as indicated by the presence of protease-resistant PrP
Sc, and showed depleted Sho levels.
(C) In Tg(OvPrP) infected with scrapie SSBP prions and Tg(ElkPrP) mice infected with elk CWD prions, Sho levels were decreased compared to age-
matched, uninfected animals. In addition to decreased Sho levels, clinically ill animals showed protease-resistant PrP
Sc in their brains. Wild-type mice
and Tg mice overexpressing mouse PrP are shown for comparison. (D) Western blot analysis of brain homogenates prepared from Tg(HuPrP,M129)
and Tg(HuPrP,V129) mice infected with human sCJD(MM1) and sCJD(VV2) prions, respectively. Clinically ill mice showed reduced levels of Sho
compared to uninfected controls. For all panels, actin levels are shown as a control. Sho was probed with the antibody 06rSH-1; PrP was detected
using antibodies HuM-D18 (A); 3F4 (B, D); or HuM-P (C), respectively. Molecular masses based on the migration of protein standards are shown in
kilodaltons.
doi:10.1371/journal.ppat.1002382.g003
Shadoo and PrP
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Sc levels in the brain since the same proportional decrease in
Sho was observed in RML-infected Tg(MoSho) mice despite much
higher levels of Sho expression. In two lines of RML-infected
Tg(HuSho) mice, Sho levels were also reduced compared to
uninfected controls (Figure 8D). When taken together, these
results argue that although Sho and PrP
Sc levels are inversely
correlated, Sho levels do not affect the onset of prion disease in
mice.
The N-terminus and GPI anchor in PrP influence Sho
reduction
In order to gain mechanistic insight into the diminution of Sho
protein during prion disease, we examined Sho levels in prion-
infected transgenic mice that express various PrP constructs.
Tg9949 mice express N-terminally truncated PrP lacking residues
23–88 at ,166the PrP levels found in wt mice. These mice are
susceptible to prion disease, albeit with longer-than-expected
incubation periods [49]. We inoculated Tg9949 mice with three
different mouse-passaged prion strains: RML, 22L, and 301V.
Tg9949 mice were susceptible to all three strains with mean
incubation periods between 104 and 161 days (Table S1). Sho
levels in their brains were evaluated when the mice developed
clinical signs of prion disease. Surprisingly, Sho levels in prion-
infected Tg9949 mice were decreased by ,30% (Figure 9A),
compared to the ,70% diminution observed in prion-infected, wt
mice (Figure 9B). Despite these significant differences in Sho
levels, amounts of protease-resistant PrP
Sc were similar in Tg9949
mice and wt mice after inoculation with either RML or 22L prions
(Figure 9A). Similar results were found in Tg mice expressing full-
length PrP lacking its GPI anchor [Tg(PrP-DGPI) mice; 50].
Following infection with RML prions, levels of Sho decreased by
only ,45% in Tg(PrP-DGPI) mice compared to ,75% in wt mice
(Figure 9C, D). These results indicate that the presence of both
the N-terminus and GPI anchor of PrP significantly influence the
strong inverse relationship between PrP
Sc and Sho during prion
disease.
Correlation of Sho depletion and PrP
Sc C2 fragment
Although Sho levels are clearly correlated with protease-
resistant PrP
Sc levels, the relative ratios of Sho and PrP
Sc may
differ by prion strain. To investigate this issue, we challenged
meadow voles with three distinct prion strains (Table S1); voles
are known to be susceptible to a variety of prion strains in a PrP
sequence–independent manner [51]. In meadow voles, Sho levels
were decreased by ,90% in RML-infected animals compared to
,80% in Sc237- or 301V-infected animals (Figure 10A).
However, based on the examination of four animals per strain,
similar or higher levels of PK-resistant PrP
Sc were consistently
found in the Sc237-infected brains compared to the RML-infected
brains (Figure 10B), indicating that prion strain-specific differ-
ences in the extent of Sho reduction cannot be explained by the
relative amount of protease-resistant PrP
Sc in the brain. To test if a
different PrP
Sc species may correlate better with the extent of Sho
reduction, we digested the prion-infected meadow vole brain
homogenates with thermolysin (TL), which is a bacterial protease
that completely digests PrP
C but leaves PrP
Sc intact. Notably,
unlike PK, TL can be used to isolate full-length PrP
Sc due to an
absence of preferred cleavage sites in the N-terminal domain of
PrP [52]. When brain homogenates were digested with TL and
then deglycosylated with PNGaseF to reveal the C2 proteolytic
fragment of PrP
Sc, which corresponds to the generation of
‘‘endogenous’’ protease-resistant PrP in prion-infected cells due
to intracellular proteolysis [19,53], a significant inverse relation-
ship between Sho and PrP
Sc C2 fragment levels was found for the
three prion strains (Figure 10B, C). For example, brains from
meadow voles infected with RML prions exhibited the lowest Sho
level and the highest PrP
Sc C2 fragment level. No C2 fragment
was observed in uninfected voles following TL digestion,
Figure 4. Decreased Sho levels in ScN2a-Sho cells. (A) Western
blot analysis of Sho levels in untransfected N2a-Sho cells. Samples were
treated with PNGaseF to remove N-glycans, as indicated. Blots were
probed with anti-Sho antibodies 06rSH-1 (top blot) and 06SH-3a
(bottom blot) recognizing N-terminal and C-terminal Sho epitopes,
respectively. An asterisk (*) denotes a cross-reactive band of ,17 kDa,
which is also detected in N2a cells, recognized by the 06rSH-1 antibody.
Whereas both the N- and C-terminal antibodies recognize full-length,
unglycosylated Sho (,16 kDa), the C-terminal antibody also detects an
endoproteolytic Sho fragment (ShoC1 fragment). Molecular masses
based on the migration of protein standards are shown in kilodaltons.
(B) In heterogeneous ScN2a-Sho cells, Sho levels were not decreased.
However, upon further subcloning of ScN2a-Sho cells to obtain a more
uniform population of infected cells (ScN2a-Sho-1 and ScN2a-Sho-2
subclones), a notable decrease in Sho levels was observed. ScN2a-Sho
cells harbor PK-resistant PrP
Sc, as detected by the antibody HuM-D18.
Actin levels are shown as a control. Molecular masses based on the
migration of protein standards are shown in kilodaltons. (C) Quantifi-
cation of Sho levels in ScN2a-Sho-1 (n=10) and ScN2a-Sho-2 (n=5)
subclones revealed a significant decrease of 40–45% compared to the
uninfected parental cell line (n=15) (***P,0.001).
doi:10.1371/journal.ppat.1002382.g004
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PrP
Sc C2 fragment, not the PrP
C C2 fragment. A similar
relationship was observed in the brains of prion-infected
Tg(MoSho) mice. Tg24474 mice infected with RML or Me7
prions exhibited the largest reduction in Sho levels and had higher
levels of the PrP
Sc C2 fragment compared to mice infected with
301V prions, which had higher residual Sho levels and lower levels
of the PrP
Sc C2 fragment (Figure 10D). Thus, prion strain-
specific differences in the extent of Sho depletion can be explained
by the relative amount of PrP
Sc C2 fragment produced for a given
strain.
Discussion
We describe here a quantitative relationship between Sho and
protease-resistant PrP
Sc levels in the brains of prion-infected
animals. Brain Sho levels were reduced in response to numerous
natural and experimental prion strains, but not in response to the
accumulation of protease-sensitive PrP
Sc,A b, alpha-synuclein, or
tau aggregates, indicating that Sho depletion is a specific indicator
of protease-resistant PrP
Sc in the brain. Thus, our experiments, as
well as similar results presented in this issue by Westaway et al.
[54] indicate that Sho is not a mere bystander during prion disease
even though Sho levels did not modulate the kinetics of prion
replication in mice.
Sho as an indicator of PrP
Sc in the brain
The quantitative inverse relationship between Sho and
protease-resistant PrP
Sc levels in the brain suggests that the
relative levels of these two proteins are mechanistically linked. Sho
depletion occurred not only in experimentally infected rodents
(Figure 1A), but also in sheep naturally infected with scrapie
(Figure 1B), eliminating the possibility that this phenomenon
results from an artifact of intracerebral inoculation. Furthermore,
Sho reduction is not a general indicator of neuronal dysfunction or
protein aggregation because Sho levels were unaltered in the
brains of Tg mice with large quantities of either Ab, alpha-
synuclein, or tau deposits (Figure 5, S4). Because reduction of
human Sho levels occurred in response to mouse PrP
Sc
Figure 5. Unchanged Sho levels in mice with other neurodegenerative illnesses. (A) Levels of Sho in the brains of Tg(APP23) and Tg(CRND8)
mice, two Tg mousemodels of Alzheimer’s disease, were unaltered despitethe high levels of cerebral Abpresentin aged mice. Actin and amyloid precursor
protein (APP) levels are shown as controls. For comparison, Sho, APP, and Ab levels in the brain of a wt FVB mouse are shown. Sho was probed with the
antibody 06rSH-1;Ab detectedwith the antibody 6E10,andAPP with the antibody APPCT. (B) Nochange in Sho levels in either oftwo lines ofTgmicewith
a neurodegenerative disease caused by expression of mutant MoPrP(P101L). The brains of these mice have abundant levels of protease-sensitive, PTA-
precipitable PrP but do not have any PK-resistant PrP. Sho and protease-resistant PrP
Sc in wt FVB mice infected with RML prions are shownfor comparison.
Sho was detectedwith theantibody 06rSH-1 andPrP was probedwith theantibody HuM-D18.Actin levels are shown as acontrol. (C) Quantification of Sho
levels in Tg(MoPrP,P101L) mice reveal only small decreases compared to wt mice (n=3 for each group).In contrast,Sho levels in wtmiceinfected withRML
prions are decreased by ,80% (***P,0.001) compared to uninfected, wt mice. (D) Levels of Sho in the brains of Tg4053 mice overexpressing MoPrP
inoculated with the MoSP2 strain of protease-sensitive prions were similar to those in age-matched Tg4053 mice inoculated with PBS. Actin levels are
shown as a control. The presence of protease-sensitive prions in the brains of MoSP2-infected Tg4053 mice was confirmed by their ability to seed the
polymerizationofrecombinantPrPintoamyloidasdemonstratedbyincreasedThTfluorescencesignalsinRT-QuICexperiments.Showasdetectedwiththe
antibody 06rSH-1. For all Western blots, molecular masses based on the migration of protein standards are shown in kilodaltons.
doi:10.1371/journal.ppat.1002382.g005
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in response to human PrP
Sc (Figure 3D), Sho depletion is unlikely
to require species-specific contacts between Sho and protease-
resistant PrP
Sc, in contrast to the species-specific interactions
between PrP
C and PrP
Sc necessary for efficient prion replication.
Because Sho expression appears to be restricted to neurons in the
brain [1,55] and neuron-specific expression of PrP
C is sufficient to
elicit Sho depletion in prion-infected mice (Figure 1C), it is likely
that interactions between Sho and PrP
Sc in neurons are
responsible for reductions in the Sho protein. Coimmunostaining
of PrP
Sc deposits and Sho in prion-infected animals may more
precisely pinpoint the location of Sho depletion in the brain.
A recent paper has also described Sho depletion in response to
various mouse-adapted prion strains, including strain-specific
effects on Sho levels [56]. In our study, infection with all prion
strains characterized by protease-resistant PrP
Sc resulted in
substantial depletion of Sho although strain-specific responses
were also observed. For a given prion strain, Sho levels correlated
well with levels of protease-resistant PrP
Sc in the brain (Figure 2).
However, differences in the extent of Sho depletion between
different prion strains were not correlated with absolute levels of
protease-resistant PrP
Sc in the brain at the onset of clinical disease
but with relative amounts of the PrP
Sc C2 fragment (Figure 10B–
D). This finding is consistent with the much higher extent of Sho
reduction in mice infected with mouse-adapated kuru compared to
mice challenged with mouse-adapted variant CJD, which appears
to have much less endogenous truncation of PrP
Sc [56]. It will be
of interest to determine whether the extent of Sho depletion
represents a consistent biochemical signature for a given protease-
resistant prion strain that can be used to identify and classify
different prion strains.
Whether Sho levels are also decreased in the brains of patients
with sporadic or genetic prion disease remains to be determined. It
will be interesting to compare Sho levels in the brains of patients
with CJD and GSS with the variably protease-sensitive priono-
pathy (VPSPr) described recently [57]. These studies will require
the generation of antibodies directed against the human Sho
sequence that exhibit higher affinity than those currently available.
A recent study has shown that secreted forms of Sho are generated
in cells [28], suggesting that Sho may exit the brain and
measurement of these secreted Sho forms might indicate total
Sho levels in the brain. Furthermore, examination of Sho levels in
biologically accessible fluids, such as CSF, from patients with prion
disease might provide a more specific indicator of prion disease
compared to tests currently used that determine 14-3-3 and total
tau levels [58]. Sho may therefore represent the first non-PrP
marker specific for prion disease in humans.
Potential mechanisms of Sho depletion in prion-infected
brains
It is currently unknown whether decreased Sho levels in prion-
infected brains result from decreased translation or increased
turnover, although the latter seems more likely because PrP
Sc is
primarily located at the cell surface and within endocytic vesicles
[59]. Multiple lines of evidence argue that Sho is degraded via an
endocytic pathway during prion disease by a PrP
Sc-mediated
process. First, Sho levels were reduced to a much smaller extent in
prion-infected Tg9949 mice expressing N-terminally truncated
PrP(D23–88) compared to wt mice (Figure 9A and B). Deletion
of residues 23–28 or residues 51–90 from PrP has been shown to
reduce or eliminate the endocytosis of PrP
C [60,61], suggesting
that endocytosis may be necessary for efficient Sho depletion.
Second, Tg mice expressing anchorless PrP, in which endocytosis
of PrP is likely to be impaired due to an absence of the GPI anchor
and associated lipid raft targeting, also exhibited a less pronounced
Figure 6. Copurification of Sho and misfolded PrP from ScN2a-
Sho-1 cell lysates. Sho copurified with PrP molecules in lysates
prepared from ScN2a-Sho-1 cells, but not with PrP
C in N2a-Sho cells, as
demonstrated by coimmunoprecipitation analyses. Nonspecific binding
of misfolded PrP to the immunoprecipitation matrix was assessed by
performing immunoprecipitations on ScN2a cells that do not express
Sho and on ScN2a-Sho-1 cells in the absence of antibody (Mock).
Samples were not treated with PK prior to Western blotting. Sho and
PrP were probed using antibodies 06rSH-1 and HuM-D18, respectively.
Molecular masses based on the migration of protein standards are
shown in kilodaltons.
doi:10.1371/journal.ppat.1002382.g006
Table 1. Incubation periods in Tg(Sho) mice following inoculation with different prion strains.
Mean incubation period ± s.e.m. (days)
Line
Relative Sho
Expression Level RML n/n0 Me7 n/n0 301V n/n0
FVB 16 12963 8/8 14462 8/8 19362 7/7
Tg(MoSho)24474 126 12263 7/7 14163 8/8 20266 6/6
Tg(MoSho)24488 206 12261 8/8 nd nd nd nd
Tg(HuSho)479 ,16x 11964 7/7 nd nd nd nd
Tg(HuSho)3930 ,32x 11862 7/7 nd nd nd nd
n, number of ill mice; n0, number of inoculated mice. nd, not determined.
doi:10.1371/journal.ppat.1002382.t001
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D). Third, Sho levels were inversely correlated with relative levels
of the PrP
Sc C2 proteolytic fragment (Figure 10C), which is
generated via the action of lysosomal proteases, including
cathepsins [19]. Finally, coimmunoprecipation of Sho and PrP
Sc
was observed ScN2a-Sho cells (Figure 6), suggesting that Sho
Figure 7. Prion infection of transgenic mice overexpressing Sho. (A) Western blot analysis of Sho levels in the brains of Tg24474 and
Tg24488 mice that express mouse Sho at 126and 206levels, respectively, compared to wt FVB mice. Samples were treated with PNGaseF to remove
N-glycans, as indicated. Sho was detected with two anti-Sho antibodies, one that recognizes the N-terminal region (06rSH-1, top blot) and the other
recognizes C-terminal residues (06SH-3a, bottom blot). The C-terminal antibody detects an endoproteolytic fragment of Sho (ShoC1 fragment). An
asterisk (*) denotes a cross-reactive band of ,17 kDa, also observed in wt FVB mice, recognized by the N-terminal anti-Sho antibody. (B) ELISA-based
quantification of PrP
C levels in wt FVB mice; Tg24474 and Tg24488 mice overexpressing mouse Sho; and Tg3930 mice overexpressing human Sho
demonstrated that PrP
C levels were not significantly altered (P.0.05) in mice overexpressing Sho (n=3 for each genotype). (C) Kaplan-Meier survival
curves of wt and Tg(MoSho) mice infected with RML prions. No significant difference (P.0.05) was observed between the individual survival curves.
(D) PrP
C levels, PK-resistant PrP
Sc levels and glycosylation patterns after infection with RML prions were similar in Tg(MoSho) and wt FVB mice, as
determined by Western blotting. The antibody HuM-P was used to detect PrP. For comparison, PrP in uninfected FVB and uninfected Tg24474 mice is
shown. (E–J) Neuropathological analysis of RML-infected wt and Tg(MoSho) mice. Hippocampal sections from RML-infected wt (E, H); Tg24474 (F, I);
or Tg24488 (G, J) mice were either stained with haematoxylin and eosin (E–G) or with the anti-PrP antibody HuM-P (H–J). Changes associated with
prion disease, including spongiform degeneration (yellow arrows in panels E–G) and PrP deposition (brown staining in panels H–J), were apparent in
all sections. No neuropathological differences were evident between RML-infected wt and Tg(MoSho) mice. Scale bar in panel E represents 100 mm
and applies to all micrographs. CA1, CA1 pyramidal cell layer; cc, corpus callosum.
doi:10.1371/journal.ppat.1002382.g007
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Sc species in cells and be
targeted towards intracellular degradation pathways. Aggregated
PrP
Sc species are known to exhibit promiscuous binding to various
surfaces and monoclonal antibodies due to nonspecific hydropho-
bic interactions [62,63]. The observation that Sho levels were only
marginally decreased in mice propagating protease-sensitive
prions may be explained by decreased amounts of highly
aggregated, protease-resistant PrP conformers or an increase in
smaller, misfolded PrP species that are neurotoxic but are less
prone to nonspecific hydrophobic interactions and more suscep-
tible to protease digestion [64]. In agreement with this notion,
the amount of PTA-precipitable PrP
Sc-like conformers in
Tg(MoPrP,P101L) mice constitutes only ,15% of total PrP
[65], whereas a much greater proportion of PrP is PTA-
precipitable in mice infected with laboratory prion strains, such
as RML. Both full-length and N-terminally trimmed Sho species
were decreased in the brains of prion-infected Tg(MoSho) mice,
suggesting that the hydrophobic tract and C-terminal domain of
Sho are sufficient for PrP
Sc-mediated interactions that result in
Sho depletion during prion disease. Perhaps a direct interaction
between the hydrophobic tract of Sho and the homologous region
in PrP
Sc, which is conformationally altered in prion disease [13], is
responsible for the significant decrease in Sho protein levels
observed in prion-infected brains.
The role of Sho in prion disease
The quantitative link between Sho and PrP
Sc levels in the brain
suggested that Sho might be capable of modulating prion
replication. However, we found no alteration to the incubation
period, neuropathology, or PrP
Sc levels in prion-infected
Tg(MoSho) or Tg(HuSho) mice, arguing that increased levels of
Sho do not modulate prion disease. Our findings also confirm
results obtained using 22L prions and a different line of
Tg(MoSho) mice [48]. Whether or not prion replication is
altered in mice lacking Sho (Sprn
0/0) remains to be determined.
Because Sho demonstrated neuroprotective activity against
toxicity caused by Dpl and PrP(D32–121) in cultured cerebellar
granular neurons [1], it was speculated that a loss of Sho levels
during prion disease (and any associated neuroprotective activity)
in response to PrP
Sc accumulation may contribute to some of the
clinical and/or neuropathological aspects of prion disease.
However, in the absence of phenotypic data from studies on
Sprn
0/0 mice, a causative role for Sho depletion in prion disease
seems unlikely since Sho levels in Tg(MoSho) mice following
prion infection were higher than those present in uninfected, wt
mice (Figure 8A).
Although Sho levels do not influence prion disease kinetics,
further studies of Sho depletion during prion disease may reveal
important clues about the mechanism of PrP
Sc-mediated
neurotoxicity. For instance, many proteins are known to reside
in close spatial proximity to PrP
C (and presumably PrP
Sc)i nt h e
cell membrane [6,8]. Nonspecific interactions between a subset of
these proteins and aggregated PrP
Sc species may result in
increased transport to endocytic compartments, increased
turnover rates and, consequently, lower steady-state levels of
neuronal membrane proteins. Similar mechanisms are known to
be responsible for the sequestration of metastable proteins with
important functions in the cytoplasm by amyloid-like protein
species [66]. Interestingly, inhibition of the Na
+/K
+-ATPase, a
protein that binds to PrP
C [67], induces rapid spongiform change
in the brains of rats similar to that observed in prion disease [68].
Thus, even small alterations to protein levels or activity by PrP
Sc
may, over time, have deleterious consequences in the brain.
Using Sho as a tool to dissect the behavior of PrP
Sc in the cell
may therefore provide novel insight into the biology of prion
disease.
Figure 8. Sho levels in prion-infected Tg(MoSho) and
Tg(HuSho) mice. (A) Levels of Sho were decreased in RML prion-
infected Tg(MoSho) mice compared to uninfected controls. For
comparison, Sho and protease-resistant PrP
Sc levels in RML-infected,
wt FVB mice are shown. The antibody HuM-P was used to probe PrP,
and the antibody 06rSH-1 used to detect Sho. Actin levels are shown as
a control. (B) RML prion infection resulted in decreased levels of both
full-length and endoproteolytically trimmed Sho in Tg(MoSho) mice. All
samples were treated with PNGaseF. The 06SH-3a antibody recognizing
a C-terminal Sho epitope was used. (C) Quantification of Sho levels in
wt and Tg(MoSho) mice (n=3 for each group) following infection with
RML prions. In all infected mice, Sho levels decreased by ,70%
compared to uninfected mice. (D) Levels of Sho were decreased in RML
prion-infected Tg(HuSho) mice compared to uninfected controls. The
antibody HuM-P was used to probe PrP, and the antibody S-12 used to
detect Sho. Actin levels are shown as a control. For all Western blots,
molecular masses based on the migration of protein standards are
shown in kilodaltons.
doi:10.1371/journal.ppat.1002382.g008
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Ethics statement
All mouse studies were carried out in accordance with the
recommendations of the Guide for the Care and Use of Laboratory
Animals (Institute of Laboratory Animal Resources, National
Academies Press, Washington, DC); protocols were reviewed
and approved by the UCSF Institutional Animal Care and Use
Committee: "Production of transgenic mice" (AN084871-01B) and
‘‘Incubation periods of prion diseases’’ (AN084950-01A).
Analysis of Sprn mRNA levels in prion-infected mice
Sprn mRNA data was extracted from the Prion Disease
Database (PDDB) [26], which can be accessed at http://prion.
systemsbiology.net.
Western blotting
Ten percent (wt/vol) brain homogenates were prepared in
calcium- and magnesium-free PBS using an Omni Tip (Omni
International, Marietta, GA) with a Fisher Scientific PowerGen
homogenizer (Fisher Scientific, Pittsburg, PA). Homogenates were
then subjected to detergent extraction using 0.5% sodium
deoxycholate/0.5% NP-40 (in PBS) at 4uC for 30 min. Following
low-speed centrifugation (2000 6 g, 5 min, 4uC), protein concen-
tration in the supernatant was determined by the bicinchoninic acid
(BCA) assay (Pierce, Rockford, IL). For Sho blots, samples were
prepared in Laemmli SDS loading buffer containing b-mercapto-
ethanol, boiled, and then separated using self-poured 14%
polyacrylamide gels. For PrP blots, samples were prepared in 16
NuPAGE loading buffer (Invitrogen, Carlsbad, CA) containing b-
mercaptoethanol and boiled for 5 min prior to loading on NuPAGE
10% Bis-Tris gels. Following SDS-PAGE, gels were transferred to
PVDF membranes and then blocked for 2 h at room temperature
with blocking buffer [5% nonfat milk in TBS containing 0.05%
Tween-20 (TBST)]. Membranes were incubated with primary
antibody at 4uC overnight in blocking buffer. Blots were rinsed three
times with TBST, incubated with horseradish peroxidase (HRP)-
conjugated secondary antibody (BioRad, Hercules, CA) for 2 h,
rinsed three times with TBST, and then developed using the
enhanced chemiluminescent detection system (Amersham, Piscat-
away, NJ). The following primary antibodies were used: anti-mouse
Sho antibodies 06rSH-1 [recognizes MoSho(30–61)] and 06SH-3a
[recognizesMoSho(86–100), alsoused to detect sheep Sho] [1]; anti-
human Sho antibody S-12 (Santa Cruz Biotechnology, Santa Cruz,
CA); anti-PrP antibodies HuM-P [69], HuM-D18 [70], and 3F4
[71];anti-Abantibody6E10(Covance,Princeton,NJ);andanti-APP
antibody APPCT recognizing the C-terminus of both mouse and
human APP (a generous gift from Paul Fraser). To confirm equal
proteinloadingontheShoblots,membraneswerereprobed withthe
anti-actin antibody 20–33 (Sigma, St. Louis, MO).
Cell culture
Mouse N2a cells were cultured in Dulbecco’s modified Eagle
medium (DMEM) containing 10% (wt/vol) fetal bovine serum, 16
Figure 9. Sho levels in prion-infected Tg mice expressing truncated or anchorless PrP. (A) Western blots of brain homogenates from wt
mice and Tg9949 mice (DN), which express MoPrP lacking residues 23–88, after infection with RML, 22L, and 301V prions. Despite developing prion
disease and showing protease-resistant PrP
Sc in their brains, Tg9949 mice showed only slight reductions in Sho levels compared to wt mice following
prion infection. Actin levels are shown as a control. (B) Quantification of Sho levels in wt and Tg9949 mice before and after infection with RML and
301V prions. Sho levels were reduced by ,30% in prion-infected Tg9949 mice compared to the 65–75% reduction observed in infected, wt mice; this
difference was statistically significant for both RML and 301V prions (***P,0.001, n=3 for each condition). (C) Western blots of brain homogenates
from wt mice and Tg(PrP-DGPI) mice, which express GPI-anchorless MoPrP, after infection with RML prions. Sho levels were lower in infected Tg(PrP-
DGPI) mice harboring protease-resistant PrP
Sc in their brains compared to uninfected mice. (D) Quantification of Sho levels in wt and Tg(PrP-DGPI)
mice after RML inoculation. Sho levels were decreased by ,45% in prion-infected Tg(PrP-DGPI) mice compared to the ,75% reduction observed in
infected, wt mice (***P,0.001, **P,0.01, n=3 for each condition). For the Western blots, Sho and PrP were probed with the antibodies 06rSH-1 and
HuM-P, respectively. Molecular masses based on the migration of protein standards are shown in kilodaltons.
doi:10.1371/journal.ppat.1002382.g009
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maintained in a 95% air/5% CO2-humidified environment. Cells
were transfected with a mouse Sho cDNA cassette (pcDNA3.-
MoSho) [1] using Lipofectamine-2000 (Invitrogen) and single cell-
derived stable clones selected using medium containing 1 mg/ml
G418. High expressing clones, as determined by Western blotting,
were selected for further analysis and were maintained in medium
containing 0.2 mg/ml G418.
For prion infections, N2a-Sho cells were exposed to medium
containing 1% (wt/vol) brain homogenate prepared from RML-
infected CD1 mice for 3 days and then passaged 1:10 five times;
the resulting RML-infected cells were denoted ScN2a-Sho cells. In
order to obtain more uniform populations of infected ScN2a-Sho
cells, these cells were then subcloned further using limiting
dilution. For experiments, cells were seeded at a density of 1.25 6
10
5 cells/well in 6-well tissue culture plates and incubated for 7
days. Culture medium was replenished as necessary. Cells were
lysed using a buffer of 50 mM Tris-HCl, pH 7.4; 150 mM NaCl;
0.5% (wt/vol) sodium deoxycholate; 0.5% (vol/vol) NP-40,
containing Complete protease inhibitor tablets (Roche, Palo Alto,
CA). Post-nuclear supernatants were obtained following low-speed
centrifugation (2000 6g, 5 min, 4uC) and then stored at 220uC.
Enzymatic digestion of proteins
For proteinase K (PK) digestions of brain homogenates, 200 mg
of detergent-extracted protein was prepared in 60 ml PBS
containing 50 mg/ml PK (PK:protein ratio of 1:67). Digestions
were performed at 37uC for 1 h and then stopped by the addition
of NuPAGE sample buffer containing b-mercaptoethanol and
subsequent boiling. For PK digestions of cell culture lysates,
20 mg/ml PK (PK:protein ratio of 1:50) for 30 min was used.
Sarkosyl and phosphotungstic acid (PTA; pH 7.4) were then
added to final concentrations of 1% (vol/vol) and 0.7% (vol/vol),
respectively. Samples were incubated at 37uC for 1 h and then
centrifuged at 18,000 6g for 40 min. Pellets were resuspended in
16 NuPAGE sample buffer containing b-mercaptoethanol and
then boiled. For thermolysin (TL) digestions of brain homoge-
nates, 100 mg of detergent-extracted protein was prepared in 60 ml
Figure 10. Decreased Sho levels correlate with the amount of PrP
Sc C2 fragment present in prion-infected animals. (A) Quantification
of Sho levels in meadow voles before and after infection with RML, Sc237, and 301V prions. Sho levels were reduced by ,90% in RML-infected voles
compared to the ,80% reduction observed in Sc237- and 301V-infected voles (*P,0.05 as determined by one-way ANOVA, n=3–4 for each group).
(B) Western blot analysis of Sho levels in the brains of prion-infected meadow voles. Infection with RML prions resulted in the largest decrease in Sho
levels and the highest amount of PrP
Sc C2 fragment (determined after digestion with thermolysin (TL) and PNGaseF). The presence of PK-resistant
PrP
Sc indicates prion disease. (C) Correlation analysis of Sho and relative PrP
Sc C2 fragment levels in the brains of prion-infected meadow voles
(n=11). A significant, inverse correlation (P,0.001) was observed, indicating that increased production of the PrP
Sc C2 fragment is associated with
decreased Sho levels in the brain. (D) Western blot analysis of Sho levels in the brains of Tg(MoSho)24474 mice infected with RML, Me7, and 301V
prions. The largest decrease in Sho levels was observed with RML and Me7 infections, which also resulted in the largest amounts of PrP
Sc C2 fragment
(determined after digestion with TL and PNGaseF). In comparison, infection with 301V prions resulted in the smallest reduction in Sho levels and the
lowest relative level of the PrP
Sc C2 fragment. Sho and PrP were probed using the antibodies 06rSH-1 and HuM-P, respectively. Actin levels are shown
for comparison. Molecular masses based on the migration of protein standards are shown in kilodaltons.
doi:10.1371/journal.ppat.1002382.g010
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for 30 min, then stopped by the addition of PNGaseF denaturing
buffer containing EDTA (5 mM final concentration) and subse-
quent boiling. Samples were then digested with PNGaseF
according to the manufacturer’s instructions (New England
Biolabs).
Immunoprecipitations
Cell lysates were normalized using the BCA assay and then
precleared with Protein G-coupled Dynabeads (Invitrogen) for 2 h
to reduce nonspecific binding. Lysates (2 mg total protein) were
then incubated with 2 mg of anti-Sho antibody 06SH-3a for 4 h at
4uC with end-over-end rotation. Antibody-antigen complexes
were captured overnight at 4uC using Protein G–coupled
Dynabeads and then washed 3 times with PBS containing
0.05% (vol/vol) Tween-20. Captured proteins were eluted in
Laemmli SDS loading buffer by boiling and then analyzed by
Western blotting as described above.
PTA precipitations
Post-nuclear supernatants were obtained from 10% brain
homogenates by centrifugation at 700 6 g for 5 min and then
normalized for protein concentration. Sarkosyl and sodium
phosphotungstic acid (pH 7.2) were then added sequentially to
final concentrations of 2% each. Samples were incubated at 37uC
with shaking for 1 h and then centifuged at 18,0006g for 40 min.
Pellets were resuspended in 16 NuPAGE loading buffer, boiled,
and then analyzed by Western blotting.
Quantification of Sho levels
Samples were subjected to Western blotting as described above
and then quantified by densitometry (ImageJ) using serial dilutions
of Sho-containing samples as standards. All statistical analysis was
performed using GraphPad Prism software (GraphPad Software,
La Jolla, CA). Statistical differences between groups were assessed
using the Student’s t-test or one-way ANOVA (with Tukey’s
Multiple Comparison test) with a significance threshold of P,0.05.
Quantification of PrP
C by ELISA
Relative PrP
C levels in the brains of wt FVB, Tg(MoSho), and
Tg(HuSho) mice were determined on detergent-extracted, BCA
assay–normalized samples by sandwich ELISA. Immulon 4HBX
plates (Nunc, Rochester, NY) were coated overnight at 4uC with
the capture antibody HuM-D18 at a concentration of 5 mg/ml.
Following blocking for ,2 h with 1% BSA diluted in phosphate-
buffered saline containing 0.05% Tween-20 (PBST), samples
(diluted in PBS containing 0.5% Triton X-100) were added and
then incubated overnight at 4uC. After 4 washes with PBST, the
detection antibody (HRP-labeled HuM-P diluted in blocking
buffer) was added and the plate incubated for 2 h at room
temperature. Following 5 washes with PBST, the plate was
developed using TMB-Blue (Dako, Carpinteria, CA), stopped by
the addition of 1 N HCl, and then read at 450 nm using a
Spectramax 384 Plus plate reader.
Real-time quaking-induced conversion (RT-QuIC)
RT-QuIC experiments were carried out essentially as described
[46]. Briefly, 10% brain homogenates were extracted on ice with
1% (v/v) Triton X-100 for 30 min and then centrifuged at 1,000
6g for 5 min. The supernatant was then diluted 1:100 into PBS
containing 0.1% SDS and 16 N2 Supplement (Invitrogen). In
each well of a 96-well plate (BD Biosciences, Bedford, MA), 2 mlo f
the diluted, detergent-extracted brain homogenate was added to
98 ml of a reaction mixture consisting of 10 mM phosphate buffer
(pH 7.4) containing 50 mg/ml recombinant mouse PrP(89–230)
[47], 130 mM NaCl, 10 mM EDTA, and 10 mM Thioflavin T.
Lyophylized samples of recombinant PrP were resuspended
initially in 10 mM phosphate buffer (pH 5.8), aliquoted, and
stored at 280uC. Plates were sealed with a clear film (Nunc) and
then incubated in a Spectramax M2 plate reader set at 42uC.
Samples were subjected to repeated rounds of 1-min rest and 1-
min shaking, and top-read fluorescence measurements (444-nm
excitation and 485-nm emission filters) were taken every 2 min.
Fluorescence values for different samples were compared after 5 h
of incubation. Each brain sample was assayed in 8 replicates.
Mouse lines
The following lines of mice were used in this study: wt FVB or
CD-1 mice expressing the PrP-A allotype; B6.I mice expressing the
PrP-B allotype [72]; Prnp
0/0 or Prnd
0/0 mice lacking PrP or Dpl
expression, respectively [73,74]; Rcm0 Prnp
0/0 mice with ectopic
Dpl expression [9]; Tg(MoPrP)B4053 mice overexpressing mouse
PrP [75]; Tg(ElkPrP)L12584 mice expressing elk PrP [76];
Tg(OvPrP,V136)N14882 mice expressing sheep PrP [77];
Tg(HuPrP,M129)S2667 mice expressing human PrP with the
M129 polymorphism (Watts et al., manuscript in preparation);
Tg(HuPrP,V129)152 mice expressing human PrP with the V129
polymorphism [78]; Tg(MoPrP,P101L)A2866 and Tg(MoPrP,
P101L)464 mice expressing MoPrP with the analogous P102L
mutation causing GSS in humans [42,44]; Tg(MoPrPD23–
88)H9949 mice that express N-terminally truncated PrP [49];
Tg(PrP-DGPI) mice expressing MoPrP lacking its GPI anchor
[50]; Tg(MoDpl)10329 mice [38]; Tg(APP23) and Tg(CRND8)
mice, which express mutant human amyloid precursor protein
[39,40]; Tg(SNCA,A53T) mice that express mutant human alpha-
synuclein [79]; and Tg(MAPT,P301S) mice that express mutant
human tau [80].
Generation of transgenic mice
The murine Sho open reading frame (ORF) was first modified
by site-directed mutagenesis to remove a NotI site, amplified from
pcDNA3.MoSho with flanking SalI restriction sites by PCR using
the primers 59-CTATATGTCGACACCATGAACTGGACT-
GCTGCC-39 (forward) and 59-CTATATGTCGACCTAAGGC-
CGAAGCAGTTCTA-39 (reverse), digested with SalI, purified by
agarose gel electrophoresis, and then inserted into SalI-digested
and dephosphorylated cos.Tet cosmid vector [81] using T4 DNA
ligase. In cos.Tet, neuronal expression of the protein of interest is
driven by the hamster Prnp promoter. Ligation mixtures were
electroporated into bacteria and clones carrying the correct DNA
molecule identified by colony PCR and DNA sequencing.
The human Sho ORF was amplified from an IMAGE cDNA
clone (ID #4816858) with flanking HindIII and XbaI restriction
sites and then inserted into the pcDNA3 vector. Following removal
of three NotI sites using the QuikChange Multi Site-Directed
Mutagenesis kit (Agilent Technologies, Santa Clara, CA), the
HuSho ORF was amplified by PCR with flanking SalI restriction
sites using the primers 59-CTATATGTCGACACCAT-
GAACTGGGCACCCGCA-39 (forward) and 59-CTATATGTC-
GACCTAGGGCCGCAGCAGCCCCA-39 (reverse), and then
inserted into cos.Tet as described above.
Vectors containing Sho constructs were linearized by digestion
with NotI, purified by agarose gel electrophoresis, and then
microinjected into the pronuclei of fertilized eggs obtained from
FVB mice. Southern blotting of genomic DNA samples was used
to identify potential founder animals using a probe located in the
39 untranslated region of the hamster Prnp gene, and the sequences
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Tg(MoSho) and Tg(HuSho) lines were maintained by backcrossing
to wt FVB mice. Relative transgene expression levels in the brain
were determined by Western blotting and densitometry using
serial dilutions of extracts prepared from Tg(MoSho) mice in
comparison to FVB mice. Tg(NSE-MoPrP) mice, which express
MoPrP
C selectively in neurons under the control of the NSE
promoter, were generated similarly, except that microinjection was
performed in FVB/Prnp
0/0 eggs.
Prion inoculations
The following prion inocula were used in this study: mouse-
adapted scrapie strains RML, 22L, and Me7 (maintained in mice
expressing the PrP-A allotype) as well as 87V (maintained in mice
expressing the PrP-B allotype); hamster-adapted scrapie strains
Sc237 and 139H; hamster-adapted TME strains HY and DY;
mouse-adapted BSE strain 301V (passaged in mice expressing
either PrP-A or PrP-B); SSBP/1 sheep scrapie prions derived from
a pool of scrapie-infected sheep brains; CWD prions derived from
the brain of a naturally-infected elk; and human sCJD prions
obtained from the brains of patients exhibiting either the MM1 or
VV2 disease subtypes.
Brain homogenates were diluted to 1% (wt/vol) in 5% BSA and
then 30 ml was inoculated into the right parietal lobe of weanling
mice or meadow voles (obtained from a breeding colony at the
University of California Berkeley) using a 27-gauge syringe. For
hamsters, the inoculation volume was 50 ml. Inoculated animals
were monitored daily for routine health and assessed three times
per week for neurological dysfunction. Mice, hamsters, or meadow
voles were euthanized following the onset of neurological
symptoms based on standard diagnostic criteria. Brains were
removed and snap-frozen prior to storage at -80uC. All animal
studies were performed in accordance with protocols approved by
the UCSF Institutional Animal Care and Use Committee.
Neuropathology
Sampleswereimmersion-fixed in10%buffered formalin andthen
embedded in paraffin using standard procedures. Sections (8 mm)
were cut, deparaffinized, and then either stained with haematoxylin
and eosin, or processed for immunohistochemistry. Endogenous
peroxidase activity was blocked by incubation in 3% hydrogen
peroxide (in methanol) and then sections to be stained with anti-PrP
antibodies were subjected to hydrolytic autoclaving (121uCf o r
10 min in citrate buffer). Following blocking with 10% normal goat
serum, sections were incubated with primary antibody overnight at
4uC. The following antibodies were used: anti-PrP HuM-P and anti-
GFAP (Dako). Antibody binding was detected using a Vectastain
ABC peroxidase kit (Vector Laboratories, Burlingame, CA) and
visualized using 3-39-diaminobenzidine (DAB).
Supporting Information
Figure S1 Guanidine hydrochloride (GdnHCl) treatment of brain
homogenate failed to increase Sho levels observable by Western
blotting. Brain homogenates from uninfected and Sc237-infected
hamsters were extracted with 6 M GdnHCl for 1 h, diluted to 0.5 M
GdnHCl with PBS, and then proteins were precipitated by the
additionofsodiumdeoxycholate[0.1%(vol/vol)finalconcentration]
and trichloroacetic acid [10% (vol/vol) final concentration] and
incubation for 15 min at room temperature. Following centrifuga-
tion at 18,0006g for 15 min, pellets were washed once with ice cold
acetone, centrifuged, resuspended in SDS-PAGE sample buffer,
boiled, and then analyzed by Western blotting. Sho levels remained
depleted in the GdnHCl-extracted, prion-infected brains compared
to uninfected controls, indicating that the decrease in Sho levels is
not due to the formation of insoluble Sho species that are refractory
to Western blot analysis. Sho was detected using the antibody
06rSH-1. Molecular mass marker based on the migration of a
protein standard is shown in kilodaltons.
(TIF)
Figure S2 Sho levels did not decrease during amplification of
prions by protein cyclic misfolding amplification (PMCA). Sho levels
were unaltered following amplification of Sc237 prions in hamster
brain homogenate by PMCA compared to non-amplified and non-
seeded controls (3 replicates each). PMCA was performed in 10%
(wt/vol) hamster brain homogenate prepared in conversion buffer
[PBS containing 150 mM NaCl, 1% (vol/vol) Triton X-100, 4 mM
EDTA, and the Complete protease inhibitor cocktail]. PMCA
conditions were as follows: 48 cycles of 1-h incubation at 37uC
followed by a 40-s sonication pulse (8.5 power on a Misonix 3000
sonicator). Amplification of prions was confirmed by the presence of
PK-resistant PrP. Sho and PrP were probed with antibodies 06rSH-
1 and HuM-P, respectively. Molecular masses based on the
migration of protein standards are shown in kilodaltons.
(TIF)
Figure S3 Sho levels did not change in mice with Dpl-induced
cerebellar degeneration. (A) No change in Sho levels was observed
in the brains of PrP-knockout mice (Prnp
0/0), Dpl-knockout mice
(Prnd
0/0), or in aged PrP-knockout mice with ectopic expression of
Dpl (Rcm0 Prnp
0/0). (B) Sho levels were unaltered in
Tg(MoDpl)Prnp
0/0 mice, which overexpress Dpl on a Prnp
0/0
background and develop cerebellar degeneration, compared to
Tg(MoDpl)Prnp
+/+ mice, which overexpress Dpl on a wild-type
PrP background and do not exhibit any degeneration. (C)I n
RML-infected Tg(MoDpl)Prnp
+/+ mice, Dpl levels were un-
changed compared to uninfected controls. For all panels, actin
levels are shown as a control. Molecular masses based on the
migration of protein standards are shown in kilodaltons. Sho and
Dpl were detected with antibodies 06rSH-1 and E6977,
respectively. PrP was probed with the antibody HuM-D18.
(TIF)
Figure S4 Sho levels did not change in mice with neurodegen-
erative illness caused by expression of disease-associated a-
synuclein or tau mutants. Compared to wild-type controls, no
change in Sho levels were observed in the brains of clinically ill
transgenic mice expressing A53T mutant human a-synuclein
[Tg(SNCA,A53T)] associated with Parkinson’s disease or of sick
transgenic mice expressing P301S mutant human tau
[Tg(MAPT,P301S)] associated with frontotemporal dementia.
Actin levels are shown as a control. Sho was detected using the
antibody 06rSH-1. Molecular mass markers based on the
migration of protein standards are shown in kilodaltons.
(TIF)
Figure S5 Analysis of aged Tg(MoSho) and Tg(HuSho) mice. (A)
Kaplan-Meier survival curves of Tg(MoSho)24474 (black, n=4);
Tg(MoSho)24488 (green, n=11); Tg(HuSho)479 (red, n=7); and
Tg(HuSho)3930 (blue, n=7) mice. A proportion of mice from 3 of
the 4 lines exhibited late-onset (typically .500 d) neurological
symptoms. (B, C) Neuropathological analysis of the brain from a
spontaneously sick Tg(MoSho)24474 mouse sacrificed at 563 days
of age. Haematoxylin and eosin staining revealed mild vacuolation
of the midbrain (B), which was accompanied by moderate astroglial
activation as demonstrated by GFAP staining (C). These changes
are consistent with normal aging in mice. Scale bar in panel B
represents 100 mm and applies to panel C.
(TIF)
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infected with the Me7 or 301V prion strains. Brain sections from
wt FVB or Tg24474 mice infected with the indicated prion strains
were stained with haematoxylin and eosin (A–D) or with the anti-
PrP antibody HuM-P (E–H). Neuropathological changes charac-
teristic of prion disease including vacuolation, neuronal loss, and
PrP deposition were evident in all cases. No obvious neuropath-
ological differences were observed between wt and Tg24474 mice
infected with the Me7 or 301V strains, indicating that Sho
overexpression does not influence prion pathology in mice. The
hippocampus/corpus callosum is shown in all panels. Scale bar in
panel A represents 100 mm and applies to all panels.
(TIF)
Table S1 Incubation periods in mice, hamsters, meadow voles,
and various transgenic mouse lines following inoculation with
different prion strains.
(DOC)
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